ASC Transplant Eligibility in Multiple Myeloma: Elisabet E. Manasanch, MD

Video

The associate professor from The University of Texas MD Anderson Cancer Center discussed eligibility for autologous stem cell transplant in patients with multiple myeloma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Elisabet E. Manasanch, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, about eligibility for autologous stem cell transplant (ASCT) in patients with multiple myeloma.

Manasanch discussed how current treatments for patients with multiple myeloma generally do not come with significant, life-altering toxcities, however, ASCT with high-dose melphalan can be very detrimental. Some patients may experience a quality-of-life decline on treatment, Manasanch stated. Understandably, eligibility criteria are strict regarding transplant, so patients should be evaluated and treated at renowned transplant centers.

However, the criteria defining transplant eligibility may be arbitrary in many cases, and a majority of patients may, in fact, be fit enough to undergo ASCT, Manasanch explains. Although some patients may not be willing to undergo transplant, careful assessment and evaluation of individual patients is critical to ensure they are properly deemed eligible or ineligible for such a procedure, Manasanch concludes.

Recent Videos
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Related Content
© 2025 MJH Life Sciences

All rights reserved.